{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:39Z","timestamp":1793915679316,"version":"4.8.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Chronic, high-dose, oral prednisone has been the mainstay of myasthenia gravis treatment for decades and has proven to be highly beneficial in many, toxic in some way to all, and not effective in a significant minority. No patient characteristics or biomarkers are predictive of treatment response leading to many patients suffering adverse effects with no benefit. Presently, measurements of treatment response, whether taken from clinician or patient perspective, are appreciated to be limited by lack of good correlation, which then complicates correlation to biological measures. Treatment response may be limited because disease mechanisms are not influenced by corticosteroids, limits on dosage because of adverse effects, or individual differences in corticosteroids. This review evaluates potential mechanisms that underlie lack of response to glucocorticoids in patients with myasthenia gravis.<\/jats:p>","DOI":"10.3389\/fneur.2022.886625","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T08:46:19Z","timestamp":1650876379000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Corticosteroid Treatment-Resistance in Myasthenia Gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Henry J.","family":"Kaminski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Denk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol Scand."},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur Neurol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ane.12261","article-title":"Glucocorticoids in myasthenia gravis - if, when, how, and how much?","volume":"130","author":"Hoffmann","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mus.24438","article-title":"Oral corticosteroid therapy and present disease status in myasthenia gravis","volume":"51","author":"Imai","year":"2015","journal-title":"Muscle Nerve."},{"key":"B7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve."},{"key":"B8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology."},{"key":"B9","first-page":"385","article-title":"Corticotropin therapy in myasthenia gravis: indications and limitations","volume":"20","author":"Namba","year":"1970","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1212\/WNL.21.10.1008","article-title":"Corticotropin therapy in myasthenia gravis: effects, indications, and limitations","volume":"21","author":"Namba","year":"1971","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJM197201062860104","article-title":"Benefit from alternate-day prednisone in myasthenia gravis","volume":"286","author":"Warmolts","year":"1972","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Arch Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol Scand."},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","article-title":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","volume":"402","author":"Ozawa","year":"2019","journal-title":"J Neurol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","article-title":"monoclonal antibody-based therapies for myasthenia gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"BioDrugs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of oral steroid therapy for myasthenia gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve."},{"key":"B18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMc1611704","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrendo.2013.183","article-title":"Glucocorticoid sensitivity in health and disease","volume":"9","author":"Quax","year":"2013","journal-title":"Nat Rev Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13545","article-title":"Clinical trials for myasthenia gravis: a historical perspective","volume":"1413","author":"Kaminski","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"596382","DOI":"10.3389\/fneur.2020.596382","article-title":"Outcome measures in clinical trials of patients with myasthenia gravis","volume":"11","author":"Thomsen","year":"2020","journal-title":"Front Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical treatment response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurol Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mus.26910","article-title":"Correlation of quantitative myasthenia gravis and myasthenia gravis activities of daily living scales in the MGTX study","volume":"62","author":"Mcpherson","year":"2020","journal-title":"Muscle Nerve."},{"key":"B28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in AChR antibody level correlate with clinical change in MG?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve."},{"key":"B29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"706951","DOI":"10.3389\/fimmu.2021.706951","article-title":"Pleiotropic effects of glucocorticoids on the immune system in circadian rhythm and stress","volume":"12","author":"Shimba","year":"2021","journal-title":"Front Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am."},{"key":"B35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1128\/MMBR.00064-15","article-title":"The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases","volume":"80","author":"Petta","year":"2016","journal-title":"Microbiol Mol Biol Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1096\/fj.01-0245com","article-title":"Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells","volume":"16","author":"Galon","year":"2002","journal-title":"FASEB J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1073\/pnas.121455098","article-title":"Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance","volume":"98","author":"Webster","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000362724","article-title":"One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids","volume":"22","author":"Cruz-Topete","year":"2015","journal-title":"Neuroimmunomodulation."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1073\/pnas.96.3.1059","article-title":"Enhancing versus suppressive effects of stress hormones on skin immune function","volume":"96","author":"Dhabhar","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","volume":"373","author":"Barnes","year":"2009","journal-title":"Lancet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","article-title":"Use of oral corticosteroids in the United Kingdom","volume":"93","author":"Van Staa","year":"2000","journal-title":"QJM."},{"key":"B44","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2021","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","article-title":"Safety of long-term combined immunosuppressive treatment in myasthenia gravis\u2013analysis of adverse effects of 163 patients","volume":"13","author":"Rozsa","year":"2006","journal-title":"Eur J Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/WNO.0b013e3182536558","article-title":"Safety of prednisone for ocular myasthenia gravis","volume":"32","author":"Bruce","year":"2012","journal-title":"J Neuroophthalmol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1073\/pnas.0300372101","article-title":"Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects","volume":"101","author":"Schacke","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.112.194340","article-title":"Delta-9,11 modification of glucocorticoids dissociates nuclear factor-kappaB inhibitory efficacy from glucocorticoid response element-associated side effects","volume":"343","author":"Baudy","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/jcph.1388","article-title":"Population pharmacokinetics of vamorolone (VBP15) in healthy men and boys with duchenne muscular dystrophy","volume":"59","author":"Mavroudis","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00467-018-3929-z","article-title":"Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome","volume":"34","author":"Schijvens","year":"2019","journal-title":"Pediatr Nephrol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2165\/00003088-199019020-00003","article-title":"Clinical pharmacokinetics of prednisone and prednisolone","volume":"19","author":"Frey","year":"1990","journal-title":"Clin Pharmacokinet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1517\/17425255.2014.878703","article-title":"Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction","volume":"10","author":"Matoulkova","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1172\/JCI26283","article-title":"Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation","volume":"116","author":"Zhou","year":"2006","journal-title":"J Clin Invest."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1007\/s10620-012-2293-2","article-title":"Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta-analysis","volume":"57","author":"Chen","year":"2012","journal-title":"Dig Dis Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3109\/08916934.2013.830714","article-title":"Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study","volume":"46","author":"Zou","year":"2013","journal-title":"Autoimmunity."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00296-015-3235-z","article-title":"Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis","volume":"35","author":"Quax","year":"2015","journal-title":"Rheumatol Int."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ene.13040","article-title":"GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis","volume":"23","author":"Xie","year":"2016","journal-title":"Eur J Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fneur.2017.00230","article-title":"The role of osteopontin and its gene on glucocorticoid response in myasthenia gravis","volume":"8","author":"Xie","year":"2017","journal-title":"Front Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1164\/ajrccm.159.5.9804131","article-title":"Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma","volume":"159","author":"Hamid","year":"1999","journal-title":"Am J Respir Crit Care Med."},{"key":"B65","first-page":"2383","article-title":"A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis","volume":"28","author":"Derijk","year":"2001","journal-title":"J Rheumatol."},{"key":"B66","first-page":"339","article-title":"Glucocorticoid receptor beta splice variant expression in patients with high and low activity of systemic lupus erythematosus","volume":"45","author":"Piotrowski","year":"2007","journal-title":"Folia Histochem Cytobiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/cts.12961","article-title":"Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients","volume":"14","author":"Lucafo","year":"2021","journal-title":"Clin Transl Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar1448","article-title":"p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis","volume":"7","author":"Yamanishi","year":"2005","journal-title":"Arthritis Res Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/cells10102529","article-title":"Acquired glucocorticoid resistance due to homologous glucocorticoid receptor downregulation: a modern look at an age-old problem","volume":"10","author":"Spies","year":"2021","journal-title":"Cells."},{"key":"B70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/tpj.2011.55","article-title":"Inter-ethnic differences in lymphocyte sensitivity to glucocorticoids reflect variation in transcriptional response","volume":"13","author":"Maranville","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.crohns.2014.06.013","article-title":"In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease","volume":"8","author":"Maranville","year":"2014","journal-title":"J Crohns Colitis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1378\/chest.127.2.571","article-title":"Racial differences in T-lymphocyte response to glucocorticoids","volume":"127","author":"Federico","year":"2005","journal-title":"Chest."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpnec.2020.100001","article-title":"Metabolites and metabolic pathways associated with glucocorticoid resistance in pregnant African-American women","author":"Corwin","year":"2020","journal-title":"Compr Psychoneuroendocrinol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ajhg.2013.08.005","article-title":"Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity","volume":"93","author":"Maranville","year":"2013","journal-title":"Am J Hum Genet."},{"key":"B75","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/ni0901-777","article-title":"Sex differences in autoimmune disease","volume":"2","author":"Whitacre","year":"2001","journal-title":"Nat Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nri.2017.38","article-title":"Immunological implications of pregnancy-induced microchimerism","volume":"17","author":"Kinder","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2815","article-title":"The X chromosome in immune functions: when a chromosome makes the difference","volume":"10","author":"Libert","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41580-021-00438-7","article-title":"Gene regulation in time and space during X-chromosome inactivation","volume":"23","author":"Loda","year":"2022","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"673068","DOI":"10.3389\/fimmu.2021.673068","article-title":"Gender may influence the immunosuppressive actions of prednisone in young patients with inflammatory bowel disease","volume":"12","author":"Lucafo","year":"2021","journal-title":"Front Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/978-3-319-73585-6_11","article-title":"Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry","volume":"50","author":"Lee","year":"2018","journal-title":"Muscle Nerve."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/NXI.0000000000000507","article-title":"Gender differences in prednisone adverse effects: survey result from the MG registry","volume":"5","author":"Lee","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B84","doi-asserted-by":"publisher","first-page":"ra74","DOI":"10.1126\/scisignal.2001077","article-title":"Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence","volume":"3","author":"Duma","year":"2010","journal-title":"Sci Signal."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.886625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T08:46:23Z","timestamp":1650876383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.886625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":84,"alternative-id":["10.3389\/fneur.2022.886625"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.886625","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"886625"}}